The Impact of Collaborative and Risk-Sharing Innovation Approaches on Clinical and Regulatory Cycle Times

Therapeutic Innovation and Regulatory Science

Volumn 48, Issue 4, 2014, Pages 482-487

  DiMasi, Joseph A ^a   Kim, Jennifer ^a   Getz, Kenneth A ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acquisitions; co development; development cycle time; development pipeline forecasting; in licensing; joint ventures; mergers; regulatory cycle time

Indexed keywords

ARTICLE; DRUG APPROVAL; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; LICENSING; PLANNING; PRIORITY JOURNAL; QUALITY CONTROL; DRUG DEVELOPMENT; HUMAN; JOINT VENTURE; PROCESS DEVELOPMENT;

ANALGESIC AGENT; ANESTHETIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; DRUG; GASTROINTESTINAL AGENT; HORMONES AND AGENTS ACTING ON THE ENDOCRINE SYSTEM; IMMUNOLOGIC AGENT; RESPIRATORY TRACT AGENT;

EID: 84903517808     PISSN: 21684790     EISSN: 21684804     Source Type: Journal    
DOI: 10.1177/2168479014521419     Document Type: Article

References (9)

1. Getz KA,Kaitin KI.Open innovation: the new face of pharmaceutical research and development.Expert Rev Clin Pharmacol. 2012;5:481-483.
2. EvaluatePharma. World Review Report 2014. 2009: 6.
3. DiMasi JA,Feldman L,Seckler A,Wilson A.Trends in risks associated with new drug development: success rates for investigational drugs.Clin Pharmacol Ther. 2010;87:272-277.
4. SharplesJPoulsenH. Externalization: is it working? The increase use of licensing and external sourcing of compounds has become a key strategy for most large pharma companies, but analysis reveals a marked discrepancy between the performance of in-licensed and self-originated compounds. http://www.thefreelibrary.com/Externalization%3A+is+it+working%3F+The+increased+use+of+licensing+and.-a0238344189. Published July 1, 2010. Accessed on March 15, 2013.
5. Getz KA,Zuckerman R,DiMasi JA,Kaitin K.Drug development portfolio and spending practices after mergers and acquisitions.Drug Information Journal. 2009;43:493-500.
6. Danzon P,Epstein A,Nicholson S2007:307-328.
7. Comanor W,Scherer F.Mergers and innovation in the pharmaceutical industry.J Health Econ. 2013;32:106-113.
8. Drug Price Competition and Patent Term Restoration Act. Pub L No. 98-417 (1984).
9. DiMasi JA,Faden L.Factors associated with multiple FDA review cycles and approval phase times.Drug Information Journal. 2009;43:201-225.